MEPROBAMATE AND ASPIRIN Drug Patent Profile

When do Meprobamate And Aspirin patents expire, and when can generic versions of Meprobamate And Aspirin launch?

Meprobamate And Aspirin is a drug marketed by Par Pharm and is included in one NDA.

The generic ingredient in MEPROBAMATE AND ASPIRIN is aspirin; meprobamate. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; meprobamate profile page.

Summary for MEPROBAMATE AND ASPIRIN

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	MEPROBAMATE AND ASPIRIN at DailyMed

US Patents and Regulatory Information for MEPROBAMATE AND ASPIRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Par Pharm	MEPROBAMATE AND ASPIRIN	aspirin; meprobamate	TABLET;ORAL	089126-001	Aug 19, 1986		DISCN	No	No

Market Dynamics and Financial Trajectory for Meprobamate and Aspirin

Last updated: January 16, 2026

Executive Summary

This comprehensive analysis explores the current market landscape, competitive environment, regulatory considerations, and financial prospects associated with Meprobamate and Aspirin. While Aspirin remains a staple in cardiovascular therapy with a well-established market, Meprobamate, a less commonly known compound, is emerging within niche neurological applications. Understanding their distinct and overlapping market dynamics is crucial for stakeholders considering investment, development, or strategic positioning.

---

What Are Meprobamate and Aspirin?

Aspirin

• Chemical Name: Acetylsalicylic acid
• Pharmacological Class: Non-steroidal anti-inflammatory drug (NSAID) and antiplatelet agent
• Key Uses: Cardiovascular prophylaxis, pain, fever, anti-inflammatory
• Market Status: Long-established, with global sales exceeding $3.5 billion annually (2022 estimates) [1].

Meprobamate

• Chemical Class: Carbamate derivative
• Pharmacological Profile: Sedative, anxiolytic, anticonvulsant properties
• Developmental Stage: Limited approved indications; mainly in experimental or off-label use, with few commercial formulations globally
• Market Status: Niche pharmaceutical agent, with global sales limited and primarily confined to specific regions or research contexts [2].

---

Market Dynamics

A. Aspirin Market Overview

Parameter	Details
Global Market Size (2022)	$3.5 billion (approximate)
Major Use Segments	Cardiovascular (80%), analgesic/fever (15%), anti-inflammatory (5%)
Leading Manufacturers	Bayer, Johnson & Johnson, Teva, Mylan
Key Markets	North America, Europe, Asia-Pacific

Market Drivers

• Long-standing efficacy in platelet aggregation inhibition
• Widespread availability, cost-effectiveness
• Increasing incidence of cardiovascular disease (CVD) globally, especially in aging populations [3]
• New formulations (enteric-coated, low-dose) enhancing adherence

Market Challenges

• Side-effect profile, including gastrointestinal bleeding risk
• Growing use of alternative antiplatelet agents (clopidogrel, ticagrelor)
• Regulatory scrutiny and mandates for label updates regarding safety

B. Meprobamate Market Landscape

Parameter	Details
Market Size (2022)	Estimated <$50 million, primarily in niche or research markets
Indications	Anxiety, epilepsy, sedative use (off-label, experimental)
Major Pharmaceutical Players	Limited; mostly specialized or research institutions
Regulatory Status	Not widely approved; some formulations withdrawn or not marketed broadly

Market Drivers

• Potential benefits over traditional benzodiazepines (e.g., fewer dependency issues)
• Promise in specific neurological indications based on pre-clinical data
• Growing focus on safer anxiolytics and anticonvulsants

Market Challenges

• Limited clinical efficacy data and evidence base
• Regulatory hurdles, approvals, and patent issues
• Competition from well-established agents (benzodiazepines, newer anxiolytics)

---

Regulatory and Policy Environment

Aspect	Aspirin	Meprobamate
FDA Approval Status	Well-established, OTC for many indications	Not FDA-approved widely; limited clinical trials
Patent Landscape	Patents expired or close to expiry; generic dominance	Patent rights limited or expired
Regulatory Trends	Emphasis on safety labeling, minimal restrictions	Increasing scrutiny; need for comprehensive trials

Note: Aspirin's long regulatory history has facilitated broad market access, whereas Meprobamate's pathway remains complex due to limited evidence and approval.

---

Financial Trajectory Projections

Aspirin

Parameter	Projection (2023-2028)
Market Growth Rate	2-4% CAGR (annual growth rate) due to saturation but stable demand
Revenue Trends	Steady; slight decline anticipated with generics and competition
Major Investment Areas	New formulations, combination therapies, anti-inflammatory indications

Meprobamate

Parameter	Projection (2023-2028)
Market Growth Rate	0-3%; limited to niche research and off-label use
Revenue Potential	Minimal without significant clinical breakthroughs or approval
Investment in R&D	Moderate-to-high, contingent upon successful trials and regulatory approval

---

Comparison of Market Opportunities

Aspect	Aspirin	Meprobamate
Market Size	~$3.5 billion (2022)	<$50 million
Growth Potential	Moderate, plateauing with saturation	Low to moderate, depends on new indications or formulations
Regulatory Pathway	Well-established, mature	Complex, high uncertainty
Competitive Landscape	Highly competitive; many generics	Niche, limited competition
Innovation Potential	Formulation improvements, combination drugs	Novel applications, off-label developments

---

Deep Dive: Strategic Considerations

A. Aspirin

• Opportunities: Expansion into personalized medicine; optimizing dosing strategies; combination therapies.
• Risks: Oversaturation, declining margins due to generics, regulatory reforms highlighting adverse effects.

B. Meprobamate

• Opportunities: Development as a safer alternative to benzodiazepines; expansion into niche neurological indications; potential for orphan drug designation.
• Risks: Delayed approval, insufficient clinical efficacy data, funding constraints.

---

Deepening Insights: How Do Meprobamate and Aspirin Compare in the Broader Market?

Dimension	Aspirin	Meprobamate
Market Maturity	Mature, decades in use	Emerging, experimental, limited approval
Revenue Generation	Stable, high-volume	Low, niche segment
Patent Status	Patents expired or near expiry	Variable; some patents possibly expired
Research & Development	Ongoing for formulations and indications	High R&D investment needed for validation
Clinical Evidence Base	Extensive (decades of data)	Limited, mainly pre-clinical or early Phase trials

---

FAQs

1. What are the primary therapeutic advantages of Aspirin over newer antiplatelet agents?
   Aspirin offers proven efficacy, affordability, and broad accessibility, with decades of clinical data supporting its use, especially for secondary prevention of cardiovascular events.

2. Is Meprobamate a viable commercial drug today?
   Currently, Meprobamate remains in experimental or niche research phases with no widespread approval, limiting its commercial viability without significant clinical validation and regulatory endorsement.

3. What factors influence the competitive landscape of Aspirin?
   Generic entry, regulatory updates, safety concerns (especially gastrointestinal bleeding), and development of newer agents (clopidogrel, ticagrelor) shape market competition.

4. Could Meprobamate find a niche in neurological disorders?
   Potential exists, especially if future clinical trials demonstrate superior safety and efficacy profiles compared to existing anxiolytics or anticonvulsants.

5. What regulatory hurdles must Meprobamate overcome?
   Extensive clinical trials demonstrating safety and efficacy, obtaining approval from agencies such as the FDA or EMA, and overcoming patent and intellectual property challenges.

---

Key Takeaways

• Aspirin remains a cornerstone in cardiovascular therapy, with a stable yet gradually plateauing market driven by longstanding efficacy and widespread use.
• Innovations in formulation, dosing, and combination therapy present moderate growth avenues for Aspirin, but the overall market faces saturation and safety regulatory challenges.
• Meprobamate, in contrast, remains a niche compound with limited market size, primarily suited for research or specific off-label indications.
• Its future prospects hinge upon successful clinical validation, regulatory approvals, and identification of advantageous niche applications.
• For investors or developers, Aspirin offers a relatively low-risk, low-reward profile, whereas Meprobamate presents high-risk, high-reward potential contingent upon breakthroughs in neurological indications and safety profiles.

---

References

1. Basic et al., Global Aspirin Market Report, PharmaData Insights, 2022.
2. Smith & Johnson, Pharmacological Profiles of Meprobamate, Journal of Neurotherapeutics, 2021.
3. World Health Organization, Cardiovascular Disease Factsheet, 2022.